Press
Release: Biotech
Holdings receives second Sucanon order from Wal-Mart
Robert Rieveley,
President of Biotech Holdings (OTC BB: BIOHF) announced today that the Company
has received its second purchase order for its Sucanon diabetes drug from
Wal-Mart.
"I am pleased to report that
we have now received a second order from Wal- Mart Stores in Mexico. This order
is from Wal-Mart's Supercenter stores division. This order increases to 137 the
total number of Wal-Mart stores in Mexico to which we are supplying Sucanon.
There are 89 Wal-Mart Supercenter stores and 48 Superama stores. Both divisions
have stores in all regions of Mexico," Mr. Rieveley said.
"We will be announcing
shortly the starting date for our television advertising, co-ordinated with
Sucanon availability in Wal-Mart stores nationally across Mexico," Mr.
Rieveley said.
To view the full press release
please visit: http://biz.yahoo.com/prnews/050427/to091.html?.v=4
Biotech
Holdings (BIOHF)
"Sucanon
is one of only three drugs approved anywhere in the world, belonging to a new
category of drugs called 'insulin sensitizers'."
Website:
www.biotechltd.com
Overview
Biotech Holdings Ltd. is an
integrated pharmaceutical company based in Vancouver, Canada, engaged in
research, development, manufacture and marketing of pharmaceutical products.
The focus of the Company is the
manufacturing and international marketing of SucanonTM, a new drug for the
treatment of Type II Diabetes.
Type II Diabetes affects more than
18 million people in North America, over 20 million in Latin America and over
150 million worldwide.
Investment Highlights
- Sucanon is one of only three
drugs approved anywhere in the world, belonging to a new category of drugs
called "insulin sensitizers".
- Sucanon has received
regulatory approval in Mexico. Mexico is the eighth largest pharmaceutical
market and one of the largest diabetic markets in the world. Complications
of diabetes is Mexico's leading cause of death.
- Sales of the drug began in
Mexico in early 2005. Sucanon is now sold in more than 600 stores
nationally in Mexico including outlets of at least six drugstore chains.
- Sucanon has been approved in
Peru and sales are planned to begin later this year. Preliminary
distribution agreements for Sucanon have been negotiated in other Latin
American countries.
- Internet sales of Sucanon
are also planned.
Product Information
Sucanon acts to
increase the body's ability to utilize its insulin, resulting in improved
metabolism and an enhanced sense of well-being for the patient. This increased
insulin sensitivity results in decreased blood sugar levels in those suffering
from Type II Diabetes. Sucanon is one of only three drugs approved anywhere in
the world, belonging to a new category of drugs called "insulin sensitizers".
1. Insulin
binding to receptors and entering the cell, (which is impeded in NIDDM
patients), is essential for the uptake of glucose 2. Sucanon increases
the binding of insulin to its receptors 3. Sucanon increases the
internalization of insulin 4. As a result, Sucanon increases the
intracellular level of insulin, which then increases the uptake of glucose .
Type II Diabetes
Type II Diabetes, or Non-Insulin
Dependent Diabetes Mellitus (NIDDM), is the most common form of Diabetes. While
Type I or Insulin-Dependent Diabetes typically becomes evident in childhood and
is due to an inborn lack or complete absence of insulin production, Type II
Diabetes typically becomes evident in adulthood and is significantly due to the
patient's lifestyle. Of all diabetics, 85% to 90% are Type II. In many
countries, the incidence of Type II Diabetes has been rising sharply in recent
decades, while the average age of onset has been declining. Type II Diabetes
affects more than 17 million people in North America, over 20 million in Latin
America and over 150 million worldwide.
Marketing
Marketing and distribution of
Sucanon has been discussed with strong pharmaceutical partners in Argentina,
Brazil, Chile, and Venezuela, with other key Latin American markets expected
to follow. Developments are expected in the current year. Also, discussions
are underway to identify a suitable development partner for North American and
Western European markets.
Production
Production of Sucanon key ingredients is
carried out at Biotech's plant in suburban Vancouver, tableting and packaging
is done in Mexico City.
Disclaimer
SmallCapReview.com feature stock reports are
intended to be stock ideas, NOT recommendations. Please do your own research
before investing. It is crucial that you at least look at current SEC filings
and read the latest press releases. Information contained in this report was
extracted from current documents filed with the SEC, the company web site and
other publicly available sources deemed reliable. For more information see our
disclaimer section, a link of which can be found on our web site. This document
contains forward-looking statements, particularly as related to the business
plans of the Company, within the meaning of Section 27A of the Securities Act of
1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ materially
from the Company's expectations and estimates. The information provided herein
is not intended for distribution to, or use by, any person or entity in any
jurisdiction or country where such distribution or use would be contrary to law
or regulation or which would subject us to any registration requirement within
such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports released to the
public through this web site, e-mail or any other means of transmission are not
to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site
or mentioned in our reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to be construed as
a solicitation or recommendation to buy or sell securities. As with any stock,
companies we select to profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their investment if they decide
to make a purchase in any of our profiled companies. Past performance of our
profiled stocks is not indicative of future results. The accuracy or
completeness of the information on our web site or within our reports is only as
reliable as the sources they were obtained from. The profile and opinions
expressed herein are expressed as of the date the profile is posted on site and
are subject to change without notice. No investor should assume that reliance on
the views, opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold positions in securities mentioned herein,
and may make purchases or sales in such securities featured on our web site or
within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SmallCapReview.com will disclose in it's
disclaimer, what, if any compensation was received for our efforts in
researching, presenting and disseminating this information to our subscriber
database and featuring the report on the SmallCapReview.com web site.
SmallCapReview.com has been compensated two thousand dollars by a third party
for its efforts in presenting the Biotech Holdings profile on its web site
and distributing it to its database of subscribers. SmallCapReview.com may
decide to purchase or sell shares on a voluntary basis in the open market
before, during or after the profiling period of this report. Information
presented on our web site and within our reports contain "forward looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Any statements that
express or involve discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, goals, assumptions or future
events or performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on expectations,
estimates and projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results or events to
differ materially from those presently anticipated. Forward looking statements
in this action may be identified through the use of words such as
???expects??™???, ???will,??? ???anticipates,??? ???estimates, ???believes,???
or that by statements indicating certain actions ???may,??? ???could,??? or
???might??? occur.
THE READER
SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN
ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND
CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its web
site.
|
